Literature DB >> 6437848

Development of tolerance to the anticonvulsant effect of diazepam in dogs.

H H Frey, H P Philippin, W Scheuler.   

Abstract

In dogs the development of tolerance to the anticonvulsant effect of diazepam was followed by weekly determinations of the convulsive threshold for pentetrazole, 10-15 min after intravenous (i.v.) injection of 0.25 or 0.5 mg/kg diazepam. As soon as after 1 week of oral treatment with diazepam, 0.25 or 0.5 mg/kg three times daily (t.i.d.), the pentetrazole threshold showed a decline or even a fall to the control level in spite of unaltered or rising concentrations of diazepam and its active metabolites. Tolerance also developed when the dogs were treated with chlorazepate, 2 mg/kg t.i.d., between the weekly diazepam injections for threshold determination. The results favor a functional type of tolerance since there was no indication of a more rapid inactivation of diazepam. Treatment with desmethyldiazepam (2 mg/kg i.v. for threshold determination and oral treatment with the desmethyldiazepam precursor chlorazepate, 2 mg/kg t.i.d.) did not produce tolerance. In further experiments in dogs anesthetized, relaxed with suxamethonium and ventilated, a spike-wave activity in the EEG was induced and maintained by an injection and subsequent infusion of pentetrazole. Out of 6 dogs, receiving 4-5 i.v. injections of 0.25-0.5 mg/kg diazepam, 2 showed the phenomenon of acute tolerance, i.e. the effect of the drug on the spiking activity in the EEG became less from one injection to the next, and thus paralleled a situation which may be observed during treatment of clinical status epilepticus. No acute tolerance was observed in corresponding experiments with desmethyldiazepam.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437848     DOI: 10.1016/0014-2999(84)90365-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Tolerance to the benzodiazepine diazepam in an animal model of anxiolytic activity.

Authors:  D N Stephens; H H Schneider
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Physical dependence on diazepam in the dog: precipitation of different abstinence syndromes by the benzodiazepine receptor antagonists Ro 15-1788 and ZK 93426.

Authors:  W Löscher; D Hönack; C P Fassbender
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 3.  Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

Review 4.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

5.  Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam.

Authors:  J J Byrnes; L G Miller; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Withdrawal precipitation by benzodiazepine receptor antagonists in dogs chronically treated with diazepam or the novel anxiolytic and anticonvulsant beta-carboline abecarnil.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

7.  Development of tolerance to anxiolytic effects of chlordiazepoxide in elevated plus-maze test and decrease of GABAA receptors.

Authors:  S Ishihara; M Hiramatsu; T Kameyama; T Nabeshima
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy.

Authors:  T Pullar; J R Haigh; S Peaker; M P Feely
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

9.  N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

Authors:  J R Haigh; T Pullar; J P Gent; C Dailley; M Feely
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

10.  Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.

Authors:  Barry E Gidal; Robert T Wechsler; Raman Sankar; Georgia D Montouris; H Steve White; James C Cloyd; Mary Clare Kane; Guangbin Peng; David M Tworek; Vivienne Shen; Jouko Isojarvi
Journal:  Neurology       Date:  2016-09-28       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.